Malignant pericardial tamponade in a patient with hormone-refractory prostate cancer

被引:0
|
作者
Tomonori Minagawa
Yasushi Murata
Shinichiro Uchikawa
Takeshi Uehara
机构
[1] Azumino Red Cross Hospital,Department of Urology
[2] Azumino Red Cross Hospital,Department of Cardiovascular Medicine
[3] Shinshu University School of Medicine,Department of Laboratory Medicine
关键词
Prostate cancer; Pericardial metastasis; Prostate-specific antigen;
D O I
暂无
中图分类号
学科分类号
摘要
An 82-year-old man who was receiving treatment for prostate cancer and cholangiocellular carcinoma was admitted to our hospital because of chest discomfort and dyspnea. At the time of admission, 16 months after the start of hormone therapy, the prostate-specific antigen level was 454.08 ng/ml. Chest radiography revealed cardiomegaly, and ultrasonography demonstrated significant pericardial effusion. Pericardiocentesis yielded a hemorrhagic exudate, and a routine cytological study revealed malignant cells. It was difficult to determine whether these cells had originated from the prostate cancer or the cholangiocellular carcinoma. However, immunohistochemical analysis of a cell-block section of the pericardial effusion allowed a diagnosis of pericardial metastasis from the prostate cancer. After drainage and intrapericardial injection of cisplatin, the amount of effusion was decreased. After removal of the pericardial drain, the patient was discharged, but the pericardial effusion was found to have accumulated again 1 month later.
引用
收藏
页码:101 / 103
页数:2
相关论文
共 50 条
  • [41] Neuroendocrine differentiation and hormone-refractory prostate cancer
    Abrahamsson, PA
    PROSTATE, 1996, : 3 - 8
  • [42] METRONOMIC CYCLOPHOSPHAMIDE IN HORMONE-REFRACTORY PROSTATE CANCER
    Baldazzi, Valentina
    Tassi, Renato
    Lapini, Alberto
    Lunghi, Alice
    Carini, Marco
    Mazzanti, Roberto
    ANTICANCER RESEARCH, 2010, 30 (04) : 1459 - 1460
  • [43] Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
    Morita, Tatsuo
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2010, 3 : 39 - 41
  • [44] The patient with hormone-refractory prostate cancer: Determining who, when, and how to treat
    Kent, EC
    Hussain, MHA
    UROLOGY, 2003, 62 (6B) : 134 - 140
  • [45] Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid
    Olson, KB
    Hellie, CM
    Pienta, KJ
    UROLOGY, 2005, 66 (03) : 658E1 - 658E3
  • [46] Hormone-refractory prostate cancer: An evolving standard of care
    Small, EJ
    Reese, DM
    Vogelzang, NJ
    SEMINARS IN ONCOLOGY, 1999, 26 (05) : 61 - 67
  • [47] New therapeutic agents for hormone-refractory prostate cancer
    Roth, BJ
    SEMINARS IN ONCOLOGY, 1996, 23 (06) : 49 - 55
  • [48] Differential gene expression in hormone-refractory prostate cancer
    Fromont, G
    Chene, L
    Vidaud, M
    Mahouche, I
    Vallancien, G
    Validire, P
    Latil, A
    Cussenot, O
    MODERN PATHOLOGY, 2003, 16 (01) : 150A - 150A
  • [49] Future therapies in hormone-refractory prostate cancer - Discussion
    DiPaola, RS
    Carducci, MA
    Smith, MR
    Nelson, JB
    Thompson, IM
    UROLOGY, 2005, 65 (5A) : 17 - 17
  • [50] Predictive modelling in hormone-refractory prostate cancer (HRPC)
    Bellmunt, Joaquim
    Carles, Joan
    Albanell, Joan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (02): : 82 - 85